Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

Fig. 2

Percentage of patients with relevant medication among (a) BMI and (b) WC categories. Statistics. p values of BMI or WC vs. factors were calculated using Chi square.***p < 0.0001; **p < 0.001; *p < 0.01. ATPIII, adult treatment panel III criteria; BMI, body mass index; IISHMS, International Joint Interim Statement for the Harmonization of the Metabolic Syndrome criteria; OADs, oral antihyperglycaemic drugs; WC, waist circumference

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840